Chitra Iyer1, Xueqian Wang1, Samantha R Renusch1, Sandra I Duque1, Allison M Wehr2, Xiaokui-Molly Mo2, Vicki L McGovern1, W David Arnold3,4, Arthur H M Burghes1, Stephen J Kolb1,3. 1. Department of Biological Chemistry and Pharmacology, The Ohio State University Wexner Medical Center, Columbus, Oh, USA. 2. Center for Biostatistics, The Ohio State University Wexner Medical Center, Columbus, Oh, USA. 3. Department of Neurology, The Ohio State University Wexner Medical Center, Columbus, Oh, USA. 4. Department of Physical Medicine and Rehabilitation, The Ohio State University Wexner Medical Center, Columbus, Oh, USA.
Abstract
BACKGROUND: Spinal Muscular Atrophy (SMA) is an autosomal recessive motor neuron disease that results in loss of spinal motor neurons, muscular weakness and, in severe cases, respiratory failure and death. SMA is caused by a deletion or mutation of the SMN1 gene and retention of the SMN2 gene that leads to low SMN expression levels.The measurement of SMN mRNA levels in peripheral blood samples has been used in SMA clinical studies as a pharmacodynamic biomarker for response to therapies designed to increase SMN levels. We recently developed a postnatal porcine model of SMA by the viral delivery of a short-hairpin RNA (shRNA) targeting porcine SMN (pSMN). scAAV9-mediated knockdown of pSMN mRNA at postnatal day 5 results in denervation, weakness and motor neuron and ventral root axon loss that begins 3-4 weeks after viral delivery, and this phenotype can be ameliorated by subsequent viral delivery of human SMN (hSMN). OBJECTIVE: To determine if the effect of modulating SMN levels using gene therapy can be measured in blood. METHODS: We measured expression of pSMN mRNA and hSMN mRNA by quantitative droplet digital PCR (ddPCR). RESULTS: We found that the endogenous expression of pSMN mRNA in blood increases in the first month of life. However, there were no significant differences in blood levels of pSMN mRNA after knock-down or of human SMN mRNA after gene therapy. CONCLUSIONS: Our results, obtained in a large animal model of SMA that is similar in size and anatomy to human infants, suggest that measurement of SMN mRNA levels in blood may not be informative in SMA clinical trials involving intrathecal delivery of SMN-modulating therapies.
BACKGROUND:Spinal Muscular Atrophy (SMA) is an autosomal recessive motor neuron disease that results in loss of spinal motor neurons, muscular weakness and, in severe cases, respiratory failure and death. SMA is caused by a deletion or mutation of the SMN1 gene and retention of the SMN2 gene that leads to low SMN expression levels.The measurement of SMN mRNA levels in peripheral blood samples has been used in SMA clinical studies as a pharmacodynamic biomarker for response to therapies designed to increase SMN levels. We recently developed a postnatal porcine model of SMA by the viral delivery of a short-hairpin RNA (shRNA) targeting porcine SMN (pSMN). scAAV9-mediated knockdown of pSMN mRNA at postnatal day 5 results in denervation, weakness and motor neuron and ventral root axon loss that begins 3-4 weeks after viral delivery, and this phenotype can be ameliorated by subsequent viral delivery of humanSMN (hSMN). OBJECTIVE: To determine if the effect of modulating SMN levels using gene therapy can be measured in blood. METHODS: We measured expression of pSMN mRNA and hSMN mRNA by quantitative droplet digital PCR (ddPCR). RESULTS: We found that the endogenous expression of pSMN mRNA in blood increases in the first month of life. However, there were no significant differences in blood levels of pSMN mRNA after knock-down or of humanSMN mRNA after gene therapy. CONCLUSIONS: Our results, obtained in a large animal model of SMA that is similar in size and anatomy to humaninfants, suggest that measurement of SMN mRNA levels in blood may not be informative in SMA clinical trials involving intrathecal delivery of SMN-modulating therapies.
Authors: P E McAndrew; D W Parsons; L R Simard; C Rochette; P N Ray; J R Mendell; T W Prior; A H Burghes Journal: Am J Hum Genet Date: 1997-06 Impact factor: 11.025
Authors: Kathrin Meyer; Laura Ferraiuolo; Leah Schmelzer; Lyndsey Braun; Vicki McGovern; Shibi Likhite; Olivia Michels; Alessandra Govoni; Julie Fitzgerald; Pablo Morales; Kevin D Foust; Jerry R Mendell; Arthur H M Burghes; Brian K Kaspar Journal: Mol Ther Date: 2014-10-31 Impact factor: 11.454
Authors: Sandra I Duque; W David Arnold; Philipp Odermatt; Xiaohui Li; Paul N Porensky; Leah Schmelzer; Kathrin Meyer; Stephen J Kolb; Daniel Schümperli; Brian K Kaspar; Arthur H M Burghes Journal: Ann Neurol Date: 2015-02-09 Impact factor: 10.422
Authors: C J Sumner; S J Kolb; G G Harmison; N O Jeffries; K Schadt; R S Finkel; G Dreyfuss; K H Fischbeck Journal: Neurology Date: 2006-02-15 Impact factor: 9.910
Authors: Matthew D Mailman; John W Heinz; Audrey C Papp; Pamela J Snyder; Mary S Sedra; Brunhilde Wirth; Arthur H M Burghes; Thomas W Prior Journal: Genet Med Date: 2002 Jan-Feb Impact factor: 8.822
Authors: Stephen J Kolb; Christopher S Coffey; Jon W Yankey; Kristin Krosschell; W David Arnold; Seward B Rutkove; Kathryn J Swoboda; Sandra P Reyna; Ai Sakonju; Basil T Darras; Richard Shell; Nancy Kuntz; Diana Castro; Susan T Iannaccone; Julie Parsons; Anne M Connolly; Claudia A Chiriboga; Craig McDonald; W Bryan Burnette; Klaus Werner; Mathula Thangarajh; Perry B Shieh; Erika Finanger; Merit E Cudkowicz; Michelle M McGovern; D Elizabeth McNeil; Richard Finkel; Edward Kaye; Allison Kingsley; Samantha R Renusch; Vicki L McGovern; Xueqian Wang; Phillip G Zaworski; Thomas W Prior; Arthur H M Burghes; Amy Bartlett; John T Kissel Journal: Ann Clin Transl Neurol Date: 2016-01-21 Impact factor: 4.511
Authors: Phillip Zaworski; Katharine M von Herrmann; Shannon Taylor; Sara S Sunshine; Kathleen McCarthy; Nicole Risher; Tara Newcomb; Marla Weetall; Thomas W Prior; Kathryn J Swoboda; Karen S Chen; Sergey Paushkin Journal: PLoS One Date: 2016-03-08 Impact factor: 3.240
Authors: Stephen J Kolb; Christopher S Coffey; Jon W Yankey; Kristin Krosschell; W David Arnold; Seward B Rutkove; Kathryn J Swoboda; Sandra P Reyna; Ai Sakonju; Basil T Darras; Richard Shell; Nancy Kuntz; Diana Castro; Julie Parsons; Anne M Connolly; Claudia A Chiriboga; Craig McDonald; W Bryan Burnette; Klaus Werner; Mathula Thangarajh; Perry B Shieh; Erika Finanger; Merit E Cudkowicz; Michelle M McGovern; D Elizabeth McNeil; Richard Finkel; Susan T Iannaccone; Edward Kaye; Allison Kingsley; Samantha R Renusch; Vicki L McGovern; Xueqian Wang; Phillip G Zaworski; Thomas W Prior; Arthur H M Burghes; Amy Bartlett; John T Kissel Journal: Ann Neurol Date: 2017-12-08 Impact factor: 10.422
Authors: Eike A Strathmann; Miriam Peters; Seyyedmohsen Hosseinibarkooie; Frank W Rigo; C Frank Bennett; Phillip G Zaworski; Karen S Chen; Michael Nothnagel; Brunhilde Wirth Journal: PLoS One Date: 2018-09-06 Impact factor: 3.240